modifi
vaccinia
ankara
mva
viru
highli
attenu
poxviru
promis
properti
vector
vaccin
mva
initi
complet
full
replic
cycl
human
recipi
therefor
immunogen
similar
live
viru
vaccin
gomez
et
al
safeti
properti
resembl
inactiv
viru
vaccin
gilbert
et
al
ceber
et
al
webster
et
al
stickl
et
al
mayr
mva
recombin
express
differ
viral
heterolog
antigen
test
preclin
clinic
trial
candid
vaccin
infecti
diseas
aid
influenza
sever
acut
respiratori
syndrom
sar
human
respiratori
syncyti
viru
rsv
infect
boukhebza
et
al
gilbert
gomez
et
al
convent
mva
seed
viru
stock
consid
vaccin
manufactur
produc
chicken
embryo
fibroblast
cef
fulli
permiss
mva
use
wellestablish
protocol
altenburg
et
al
cotter
et
al
largescal
product
mva
recombin
immun
campaign
would
also
reli
propag
cef
altenburg
et
al
howev
suppli
primari
cell
cultur
challeng
larg
scale
manufactur
product
mva
recombin
investig
continu
suspens
cell
line
duck
cell
line
jordan
et
al
lohr
et
al
duck
embryon
stem
cellderiv
cell
et
al
influenza
virus
usual
process
provid
inactiv
vaccin
season
epidem
soema
et
al
product
influenza
vaccin
past
year
reli
embryon
chicken
egg
disadvantag
associ
substrat
use
animalderiv
substrat
potenti
shortag
egg
especi
case
pandem
emerg
recent
two
cell
culturebas
vaccin
produc
either
mdck
cell
insect
cell
use
baculoviru
express
vector
system
approv
fda
buckland
addit
effici
product
influenza
viru
also
shown
suspens
cell
line
includ
vero
cell
litwin
paillet
et
al
cell
pau
et
al
cell
le
ru
et
al
cell
brown
mehtali
white
et
al
well
cell
jordan
et
al
lohr
et
al
lohr
cell
culturederiv
viral
vaccin
typic
produc
biphas
process
compris
initi
cell
growth
phase
viru
replic
phase
initi
inocul
seed
viru
viral
genom
amplifi
viral
protein
produc
virion
assembl
progeni
viru
particl
releas
aunin
typic
cell
first
cultiv
batch
mode
infect
late
exponenti
growth
phase
concentr
order
cellsml
without
partial
exchang
cultur
medium
aunin
tapia
et
al
titer
wildtyp
mva
obtain
adher
cultur
cef
cell
serumcontain
medium
rang
infecti
unit
iu
per
ml
gilbert
et
al
meiser
et
al
avian
cell
line
jordan
et
al
lohr
et
al
lohr
guehenneux
pain
et
al
also
yield
titer
order
iuml
advantag
enabl
suspens
cell
cultur
process
howev
one
caveat
process
requir
induct
suspend
cell
aggreg
effici
replic
mva
novel
mva
deriv
adapt
propag
true
singlecel
suspens
cultur
without
requir
addit
medium
induc
cell
aggreg
jordan
et
al
scalabl
intensifi
process
yield
high
titer
desir
secur
adequ
suppli
vaccin
case
mva
high
viru
titer
requir
mva
replic
human
recipi
therefor
amplifi
site
inject
concentr
dose
iuml
estim
requir
clinic
applic
mva
gomez
et
al
altenburg
et
al
case
influenza
vaccin
intensif
desir
composit
multival
vaccin
chang
everi
year
time
short
select
season
viru
strain
desir
start
vaccin
increas
concentr
host
cell
standard
approach
intensifi
product
process
biolog
process
high
cell
densiti
hcd
allow
use
compact
bioreactor
high
volumetr
product
rate
adjust
viabl
cell
densiti
per
ml
clinck
et
al
cell
densiti
achiev
perfus
mode
allow
continu
addit
fresh
medium
remov
toxic
byproduct
lactat
ammonium
retain
cell
bioreactor
use
differ
retent
system
product
recombin
protein
perfus
typic
perform
highmedium
exchang
rate
media
volum
per
reactor
volum
per
day
nl
cell
day
konstantinov
et
al
maintain
cultur
prolif
state
constant
high
cell
densiti
control
continu
remov
cell
bioreactor
perform
socal
cell
bleed
clinck
et
al
et
al
hiller
et
al
novel
cultiv
strategi
perfusionhighse
fedbatch
yang
et
al
concentr
fedbatch
fb
yang
et
al
hybrid
perfus
fb
hiller
et
al
develop
minim
media
use
maintain
cellspecif
volumetr
product
well
guarante
consist
product
qualiti
field
viral
vaccin
product
high
cell
concentr
cellsml
use
propag
influenza
viru
genzel
et
al
viru
strain
vazquezramirez
et
al
cell
concentr
viru
propag
must
perform
optim
ph
temperatur
nutrient
concentr
avoid
socal
cell
densiti
effect
reduct
cellspecif
viru
yield
often
observ
concentr
exceed
cellsml
lindsay
betenbaugh
maranga
et
al
sever
improv
report
hcd
product
influenza
viru
cultiv
perform
perfus
cultur
cell
viru
propag
phase
use
acoust
filter
petiot
et
al
altern
tangenti
flow
atf
system
cell
retent
genzel
et
al
perfus
system
differ
partit
viru
wherea
acoust
filter
allow
continu
viru
harvest
atf
system
membran
pore
size
retain
releas
viral
particl
bioreactor
addit
continu
permeat
flow
hollow
fiber
membran
result
product
loss
due
unspecif
bind
membran
foul
entrap
cellular
debri
viru
particl
within
membran
pore
genzel
et
al
although
cellspecif
viru
yield
compar
convent
batch
process
obtain
cell
retent
system
volumetr
product
amount
viru
per
volum
medium
spent
time
lower
genzel
et
al
strategi
would
therefor
less
competit
increas
cost
good
cog
implement
largescal
pollock
et
al
attempt
produc
mva
viru
strain
high
concentr
cell
cellsml
perfus
use
medium
free
animalderiv
compon
implement
vazquezramirez
et
al
method
result
viru
retent
yield
lower
cellspecif
volumetr
product
compar
convent
cell
densiti
cultiv
detail
analysi
sever
cultiv
strategi
shake
flask
demonstr
fb
phase
follow
daili
medium
exchang
result
improv
cellspecif
yield
volumetr
product
even
surpass
convent
cell
densiti
process
perform
control
vazquezramirez
et
al
shake
flask
experi
essenti
character
product
process
insuffici
establish
strategi
largescal
manufactur
vaccin
henc
present
studi
optim
hcd
process
develop
control
scalabl
cultiv
system
provid
requir
high
yield
mva
viru
hcd
cultur
achiev
l
bioreactor
atf
perfus
system
use
manual
perfus
control
perfus
rate
adjust
appli
fix
cellspecif
perfus
rate
cspr
volum
medium
provid
singl
cell
per
day
ozturk
viru
product
cell
cultiv
fb
follow
continu
medium
exchang
atf
perfus
system
use
cell
prolifer
phase
hybrid
fbperfus
strategi
yield
product
process
confirm
shake
flask
result
investig
option
use
strategi
viral
vaccin
product
process
propag
influenza
viru
also
test
similar
even
higher
product
compar
convent
cell
densiti
cultiv
obtain
cell
line
name
crpix
directli
deriv
avian
cell
line
gener
muscovi
duck
retina
cell
jordan
et
al
crpix
cell
differ
progenitor
express
pix
protein
human
adenoviru
jordan
et
al
viru
relat
mva
influenza
virus
suspens
crpix
cell
cultiv
chemic
defin
medium
biochrom
gmbh
glucos
concentr
mm
supplement
glutamin
sigma
lot
alanin
sigma
lot
final
concentr
mm
addit
recombin
insulinlik
growth
factor
sigma
lot
ad
ngml
final
concentr
cell
passag
everi
day
seed
concentr
cellsml
crpix
cell
inocul
l
nomin
volum
benchtop
bioreactor
plu
sartoriu
ag
cellsml
work
volum
vw
l
tabl
bioreactor
oper
ph
stir
speed
rpm
dissolv
oxygen
concentr
control
puls
aerat
pure
oxygen
pore
size
microsparg
unit
maximum
cell
initi
cultiv
batch
glucos
concentr
mm
h
inocul
reach
point
perfus
start
use
perfus
system
control
control
refin
technolog
polysulfon
hollow
fiber
cartridg
pore
size
kda
ge
healthcar
ge
healthcar
polyethersulfon
hollow
fiber
cartridg
spectrum
lab
tabl
cell
suspens
flow
rate
within
hollow
fiber
set
lmin
defin
perfus
rate
appli
achiev
cell
densiti
cellsml
perfus
flow
rate
cell
growth
phase
adjust
manual
everi
h
viabl
cell
densiti
measur
offlin
correspond
flow
rate
sampl
time
calcul
assur
cspr
nl
cell
day
optim
exchang
rate
crpix
cell
base
glucos
consumpt
rate
vazquezramirez
et
al
expect
viabl
cell
densiti
correspond
perfus
flow
rate
h
calcul
take
account
maximum
cellspecif
growth
rate
data
shown
linear
profil
sampl
time
point
achiev
use
cascad
control
plu
modul
two
hour
infect
one
reactor
volum
exchang
fresh
medium
use
atf
system
summari
key
paramet
perfus
cultiv
present
tabl
medium
exchang
bioreactor
infect
either
influenza
viru
viru
two
bolu
feed
regim
follow
perfus
regim
name
hybrid
fig
hybrid
fig
appli
optim
viru
propag
high
cell
densiti
hybrid
onehalf
cell
suspens
discard
viru
product
phase
start
l
cell
suspens
allow
fb
volum
expans
threefold
higher
initi
vw
describ
vazquezramirez
et
al
fb
start
immedi
viru
infect
addit
l
fresh
medium
obtain
minimum
cultur
volum
bioreactor
impel
least
cm
medium
surfac
fb
continu
bolu
feed
l
h
post
infect
hpi
l
hpi
final
perfus
perform
rate
one
reactor
volum
per
day
hpi
fig
viru
particl
nm
nomin
size
harvest
use
atf
hollow
fiber
modul
pore
size
cell
growth
phase
similarli
hybrid
one
bolu
feed
l
done
immedi
viru
infect
follow
second
feed
l
hpi
subsequ
perfus
perform
rate
one
reactor
volum
per
day
hpi
fig
order
improv
viru
harvest
atf
modul
use
cell
growth
phase
replac
new
modul
hpi
influenza
viru
product
hybrid
strategi
fig
similar
one
assess
viru
establish
refer
process
one
oper
complet
perfus
total
viru
retent
one
batch
convent
cell
densiti
perform
propos
previous
genzel
et
al
detail
descript
process
paramet
cell
expans
tabl
perform
viru
propag
tabl
present
result
section
infect
viru
carri
work
bank
infecti
unit
per
ml
iuml
deriv
viru
seed
jordan
et
al
kindli
provid
probiogen
ag
viru
seed
aliquot
treat
min
sonic
water
bath
break
viru
aggreg
dilut
fresh
medium
volum
equal
bioreactor
vw
ad
cell
cultur
moi
multipl
infect
iucel
experi
viru
infecti
titer
determin
take
account
potenti
applic
live
viral
vector
jordan
et
al
vaccinia
virus
usual
replic
highli
cellassoci
fashion
therefor
quantif
total
viru
titer
intra
extracellular
cell
suspens
treat
cell
lysi
lysat
obtain
three
freezethaw
cycl
follow
min
sonic
water
bath
khz
cellular
debri
remov
centrifug
room
temperatur
min
quantif
viru
releas
host
cell
supernat
sampl
centrifug
rt
min
cellfre
supernat
also
subject
three
freezethaw
cycl
storag
jordan
et
al
viru
sampl
store
aliquot
ml
number
infecti
unit
determin
describ
previous
jordan
et
al
rel
standard
deviat
log
result
titer
express
iuml
studi
human
influenza
viru
perform
mdckderiv
viru
seed
robert
koch
institut
amp
adapt
crpix
cell
three
passag
infecti
titer
adapt
viru
seed
determin
assay
iuml
bioreactor
experi
perform
moi
presenc
u
trypsincel
gibco
prepar
pb
uml
facilit
progress
infect
oppos
mva
main
applic
influenza
viru
prepar
inactiv
vaccin
total
concentr
viral
hemagglutinin
protein
antigen
decis
reason
total
viru
particl
concentr
estim
hemagglutin
ha
assay
previous
describ
kalbfuss
et
al
ha
titer
express
log
ha
unit
per
test
volum
log
ml
convert
virionsml
assum
bind
one
viru
particl
per
erythrocyt
erythrocyt
concentr
cellsml
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
c
mathrm
viru
left
log
mathrm
hau
mathrm
ml
right
end
document
cviru
total
viru
concentr
virionsml
rel
standard
deviat
method
log
ha
kalbfuss
et
al
cellspecif
viru
yield
yvcell
calcul
base
total
ie
intra
extracellular
number
infecti
viru
particl
virt
infect
assay
mva
viru
total
number
viru
particl
cviru
ha
assay
influenza
viru
take
account
total
number
viabl
cell
time
sampl
cellt
latter
differ
number
viabl
cell
time
infect
sinc
cell
growth
typic
observ
hpi
similarli
volumetr
product
pv
calcul
consid
virt
total
spent
medium
cell
growth
viru
replic
phase
vt
l
total
process
time
tt
day
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
p
mathrm
v
mathrm
vir
mathrm
left
v
mathrm
time
mathrm
right
end
document
sampl
ml
bioreactor
cultur
taken
syring
luerlockseptum
interv
store
analysi
valid
assay
use
bioprofil
plu
nova
biomed
use
determin
glucos
lactat
concentr
describ
previous
lohr
et
al
viabl
cell
densiti
vcd
cellsml
cell
viabil
averag
cell
diamet
determin
cell
counter
xr
beckman
coulter
use
previous
valid
measur
program
rel
standard
deviat
agecr
crpix
cell
lohr
cell
analyz
total
imag
cluster
diamet
class
rang
calcul
total
viabl
cell
volum
per
cultur
volum
vcv
use
cell
number
cell
diamet
distribut
cultiv
capacit
probe
connect
arc
view
control
hamilton
bonaduz
ag
evalu
perform
deliv
onlin
vcv
data
onlin
system
configur
provid
cell
cultur
permitt
pfcm
correl
directli
vcv
onlin
permitt
convert
vcv
appli
correl
factor
obtain
previou
cultiv
data
shown
viru
process
adapt
implement
vw
bioreactor
cell
growth
phase
variant
hybrid
actual
cspr
nl
cell
day
fig
tabl
obtain
compar
target
nl
cell
day
perfus
rate
enabl
cell
expans
cellsml
fig
tabl
compar
assum
specif
growth
rate
perfus
within
rang
previou
report
batch
cultur
lohr
et
al
manual
control
cspr
cell
growth
phase
also
prevent
glucos
limit
excess
accumul
lactat
fig
altern
hybrid
hybrid
start
cellsml
cultiv
cellsml
result
cspr
averag
nl
cell
day
respect
tabl
also
accord
target
valu
nl
cell
day
contrast
hybrid
cultiv
cell
suspens
concentr
twofold
infect
reduc
work
volum
l
fig
one
reactor
volum
exchang
fresh
medium
procedur
shorten
cell
growth
phase
day
obviat
discard
half
volum
produc
cell
suspens
fig
afterward
alreadi
describ
hybrid
strategi
appli
onlin
vcv
monitor
implement
hybrid
correl
well
offlin
measur
late
stage
mva
viru
propag
phase
fig
demonstr
robust
onlin
capacit
measur
vcd
exce
cellsml
expand
measur
stage
virusinduc
cell
damag
apoptosi
wide
spread
within
infect
cell
popul
gener
manual
control
cspr
cell
growth
hybrid
strategi
appli
viru
propag
prevent
glucos
limit
excess
accumul
lactat
fig
maximum
viru
yield
iuml
obtain
hpi
hpi
hybrid
hybrid
respect
fig
hybrid
viru
particl
harvest
use
atf
hollow
fiber
modul
pore
size
cell
growth
phase
wherea
hybrid
modul
use
cell
growth
phase
replac
new
modul
perfus
viru
harvest
hpi
rel
low
viru
harvest
observ
hybrid
fig
suggest
membran
foul
might
occur
cell
growth
phase
nevertheless
similar
maximum
viru
titer
cellspecif
yield
volumetr
product
obtain
compar
refer
process
shake
flask
tabl
f
involv
daili
harvest
viru
vazquezramirez
et
al
even
signific
tenfold
increas
cellspecif
yield
volumetr
product
hybrid
compar
use
perfus
viru
propag
tabl
perfus
vazquezramirez
et
al
given
suboptim
viru
harvest
hybrid
product
collect
permeat
consid
calcul
cellspecif
yield
volumetr
product
hybrid
almost
infecti
virion
found
cultur
supernat
maximum
viru
titer
iuml
hpi
fig
agreement
previou
report
jordan
et
al
vazquezramirez
et
al
chang
hollow
fiber
modul
viru
product
phase
enabl
quantit
harvest
viru
particl
supernat
first
h
perfus
ie
hpi
fig
hpi
viru
particl
concentr
permeat
decreas
consider
respect
appar
viru
content
cultur
supernat
viru
titer
permeat
reach
iuml
hpi
maximum
viru
titer
iuml
reach
cultur
supernat
fig
decreas
permeat
viru
concentr
iuml
observ
hpi
titer
bioreactor
remain
almost
stabl
order
iuml
fig
similar
hybrid
cultiv
observ
suggest
signific
membran
foul
hpi
h
begin
perfus
preced
product
period
viru
propag
phase
occur
hpi
fig
phase
also
coincid
fast
drop
cell
viabil
like
increas
cell
lysi
result
massiv
accumul
cell
debri
aggreg
viral
particl
nm
may
eventu
led
obstruct
atf
membran
nomin
pore
size
maximum
titer
reach
hpi
infecti
virion
appear
remain
stabl
supernat
well
total
cell
lysat
obviou
decay
titer
observ
hpi
fig
despit
differ
feed
profil
fb
hybrid
variant
product
hybrid
tabl
particular
cellspecif
viru
yield
iucel
volumetr
product
iu
l
day
obtain
similar
hybrid
variant
low
amount
product
collect
permeat
line
therefor
neglect
calcul
cellspecif
yield
volumetr
product
reduc
process
time
hybrid
day
led
twofold
higher
volumetr
product
compar
cultiv
hybrid
howev
viru
yield
order
iu
l
day
would
still
expect
process
oper
similar
time
period
cultiv
hybrid
day
cellspecif
viru
yield
compar
hybrid
tabl
use
strategi
seem
reason
earlier
studi
investig
factor
interf
product
influenza
viru
hcd
gave
partial
solut
regard
product
optim
genzel
et
al
perfus
bioreactor
optim
earlier
studi
avian
cell
line
way
cellspecif
viru
yield
increas
howev
overal
volumetr
product
process
higher
batch
cultiv
perform
convent
cell
densiti
cell
line
parent
cell
line
crpix
cell
shown
higher
product
influenza
viru
contrast
product
slightli
lower
mva
viru
compar
crpix
cell
jordan
et
al
lohr
et
al
accordingli
investig
next
whether
hybrid
fbperfus
strategi
establish
mva
viru
studi
could
also
use
improv
volumetr
product
influenza
viru
crpix
cell
hcd
addit
altern
perfus
control
evalu
cell
growth
phase
base
glucos
consumpt
lactat
accumul
result
medium
acidif
accomplish
harvest
medium
feed
pump
activ
ph
drop
valu
turn
ph
increas
condit
glucos
replenish
time
lactat
remov
bioreactor
perfus
control
allow
averag
cspr
nl
cell
day
tabl
fig
cell
viabil
fig
addit
enabl
maintain
glucos
concentr
mm
fig
similar
previou
report
shake
flask
ph
control
rang
appli
cspr
l
cell
day
fresh
medium
vazquezramirez
et
al
differ
hipcop
strategi
propos
hiller
et
al
oper
glucos
limit
lactat
consumpt
regim
cho
cell
cultiv
strategi
allow
perfus
control
without
reach
low
glucos
concentr
might
neg
affect
growth
crpix
cell
crpix
cell
cultiv
cellsml
vw
reduc
l
reactor
volum
exchang
fresh
medium
viru
infect
fig
final
concentr
cellsml
measur
infect
fig
influenza
virus
report
replic
rapidli
crpix
cell
jordan
et
al
lohr
et
al
increas
ha
titer
typic
observ
hpi
depend
viru
strain
maximum
titer
obtain
hpi
lohr
et
al
base
inform
contrast
product
mva
viru
fb
phase
shorten
hpi
follow
perfus
phase
rate
one
reactor
volum
per
day
fig
process
oper
complet
perfus
total
viru
retent
propos
genzel
et
al
perform
refer
process
onlin
resourc
hybrid
cultiv
yield
maximum
ha
titer
log
virionsml
hpi
fig
repres
fivefold
increas
compar
refer
perfus
cultiv
fig
compar
convent
batch
process
tabl
increas
sevenfold
although
medium
develop
perfus
process
jordan
et
al
medium
consumpt
achiev
concentr
cellsml
csprbase
perfus
moder
reactor
volum
hybrid
reactor
volum
hybrid
despit
low
medium
util
averag
cellspecif
growth
rate
hybrid
cultiv
compar
achiev
previous
shake
flask
vazquezramirez
et
al
accordingli
also
took
day
reach
minimum
vcd
cellsml
petiot
et
al
report
medium
util
reactor
volum
expand
cell
within
day
cellsml
infect
influenza
viru
genzel
et
al
report
medium
consumpt
reactor
volum
propag
cell
cellsml
infect
influenza
viru
therefor
result
repres
signific
reduct
medium
consumpt
viru
infect
import
contribut
toward
lower
cog
largescal
product
hybrid
hybrid
variant
simplifi
product
process
singl
bioreactor
use
cell
expans
viru
propag
hybrid
cultiv
onehalf
cell
suspens
l
remov
infect
cellsml
fig
cell
suspens
could
possibl
use
start
second
bioreactor
parallel
contrast
hybrid
cultiv
cell
cultiv
cellsml
l
concentr
cellsml
prior
infect
fig
case
subsequ
fb
phase
requir
addit
almost
three
time
start
volum
avoid
substrat
limit
ratio
lower
report
pohlscheidt
et
al
highyield
product
parapoxviru
ovi
larg
scale
transfer
cell
suspens
second
larger
bioreactor
perform
dilut
step
sinc
initi
fb
phase
hybrid
strategi
seem
critic
oper
also
viru
propag
vazquezramirez
et
al
studi
could
focu
develop
optim
feed
medium
enabl
higher
start
volum
prefer
maximum
work
volum
lower
maximum
dilut
ratio
simplifi
hybrid
strategi
implement
largescal
bioreactor
overal
establish
hybrid
strategi
viru
product
tabl
hybrid
hybrid
result
increas
viru
titer
compar
current
standard
product
platform
cef
cell
gilbert
et
al
meiser
et
al
respect
cultiv
perform
convent
cell
densiti
use
crpix
cell
jordan
et
al
lohr
et
al
lohr
cell
guehenneux
pain
cell
et
al
tenfold
higher
titer
obtain
cellspecif
viru
yield
obtain
hybrid
strategi
iucel
also
competit
regard
iucel
obtain
cef
cell
carrol
moss
iucel
crpix
cell
lohr
iucel
cell
et
al
convent
lower
cell
densiti
batch
product
mva
viru
crpix
cell
jordan
et
al
lohr
cell
et
al
requir
less
time
media
volum
accordingli
volumetr
product
iu
l
day
clearli
surpass
iu
l
day
obtain
hybrid
strategi
appli
strategi
would
allow
dose
per
liter
cellfre
supernat
consid
singl
dose
pfu
pfu
iu
per
individu
current
use
clinic
studi
involv
recombin
mvabas
vaccin
gomez
et
al
due
applic
viral
vector
maintain
infecti
activ
mva
critic
qualiti
attribut
promis
titer
found
remain
stabl
hpi
fig
suggest
low
viru
inactiv
rate
specif
cultiv
condit
chosen
continu
viru
harvest
fail
chosen
atf
system
use
cell
retent
devic
includ
acoust
filter
settler
might
evalu
largescal
product
avoid
product
loss
one
major
properti
viru
capac
propag
true
singlecel
suspens
cultur
may
addit
help
facilit
recoveri
infecti
unit
directli
cultur
supernat
without
need
cell
disrupt
jordan
et
al
hybrid
cultiv
show
maximum
titer
hpi
account
entir
viru
supernat
fig
cell
show
viabil
henc
clarif
step
point
care
chosen
cell
retent
system
would
suffic
recov
viru
bioreactor
base
high
perform
hybrid
strategi
upstream
process
option
reduc
cost
downstream
process
assum
higher
cost
relat
implement
complex
perfus
process
purchas
dedic
equip
train
staff
compens
even
industri
scale
perfus
control
appli
cell
growth
phase
hybrid
cultiv
led
overal
accord
previou
hcd
bioreactor
cultiv
tabl
similar
hybrid
process
viru
onlin
vcv
estim
correl
well
offlin
measur
late
stage
influenza
viru
propag
phase
fig
glucos
limit
signific
lactat
accumul
observ
phbase
perfus
control
cell
growth
phase
fig
high
averag
cspr
nl
cell
day
tabl
fig
obtain
cell
growth
phase
led
increas
medium
consumpt
reactor
volum
compar
refer
perfus
process
reactor
volum
sinc
perfus
rate
depend
ph
control
cultiv
reduc
ph
set
point
could
minim
high
medium
exchang
despit
high
medium
consumpt
hybrid
strategi
provid
cellspecif
yield
virionscel
volumetr
product
virion
l
day
tabl
observ
confirm
cell
densiti
effect
circumv
hybrid
strategi
influenza
virusinfect
cultur
differ
volumetr
product
respect
batch
cultiv
explain
rather
high
medium
consumpt
cell
growth
phase
hybrid
cultiv
compar
perfusiononli
strategi
hybrid
fbperfus
confer
clear
improv
cellspecif
volumetr
product
tabl
show
compar
yield
influenza
viru
respect
parent
suspens
cell
line
genzel
et
al
process
intensif
consequ
use
hcd
strategi
viral
vaccin
manufactur
contribut
stabl
suppli
vaccin
case
convent
batch
product
process
alreadi
establish
implement
hcd
strategi
significantli
increas
manufactur
capac
eg
emerg
develop
countri
vaccin
urgent
need
possibl
solut
use
hybrid
fbperfus
strategi
viru
product
phase
mva
influenza
viru
small
stir
tank
bioreactor
describ
applic
strategi
result
increas
viru
titer
without
compromis
cellspecif
yield
volumetr
product
often
hinder
establish
intensifi
process
high
titer
iuml
obtain
mva
viru
demonstr
particular
potenti
approach
altern
current
technolog
reli
primari
chicken
embryo
fibroblast
substrat
result
achiev
two
differ
virus
may
also
instruct
modern
convent
approach
viral
vaccin
product
